Kymera Therapeutics (KYMR) News Today $44.81 +0.28 (+0.63%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$44.81 0.00 (0.00%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Morgan Stanley Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR)July 4 at 4:00 AM | americanbankingnews.comKymera Therapeutics (KYMR) director group buys $13.9 million in stockJuly 3 at 8:07 PM | investing.comKymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Morgan StanleyJuly 3 at 8:46 AM | marketbeat.comTuesday’s Insider Activity: Major Buys and Sells Shake Up MarketsJuly 3 at 3:51 AM | investing.comInsider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of StockJuly 2 at 5:18 AM | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bvf Partners L. P/Il Purchases 317,167 SharesJuly 1, 2025 | marketbeat.comBros. Advisors Lp Baker Purchases 655,500 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) StockJuly 1, 2025 | insidertrades.comQ3 EPS Estimate for Kymera Therapeutics Decreased by AnalystJuly 1, 2025 | americanbankingnews.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bros. Advisors Lp Baker Buys 655,500 SharesJune 30, 2025 | marketbeat.comResearch Analysts Set Expectations for KYMR FY2026 EarningsJune 30, 2025 | americanbankingnews.comHC Wainwright Has Strong Forecast for KYMR FY2026 EarningsJune 30, 2025 | marketbeat.comKYMR Q3 EPS Estimate Reduced by Brookline Capital ManagementJune 30, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Here's WhyJune 29, 2025 | americanbankingnews.comOppenheimer Lowers Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00June 29, 2025 | americanbankingnews.comWells Fargo & Company Issues Pessimistic Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock PriceJune 28, 2025 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Trading Down 4.1% Following Analyst DowngradeJune 28, 2025 | americanbankingnews.comOppenheimer Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00June 27, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Time to Buy?June 27, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Kymera Therapeutics (NASDAQ:KYMR)June 27, 2025 | americanbankingnews.comKymera Therapeutics Announces Pricing of $250 Million Public OfferingJune 26, 2025 | globenewswire.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 4.1% Following Analyst DowngradeJune 26, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Price Target Lowered to $53.00 at Wells Fargo & CompanyJune 26, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC WainwrightJune 26, 2025 | marketbeat.comKYMR Kymera Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comKymera signs $750M Gilead deal, announces $250M stock offeringJune 26, 2025 | bizjournals.comKymera Therapeutics Announces Proposed Public OfferingJune 25, 2025 | globenewswire.comKymera Therapeutics (NASDAQ:KYMR) Shares Gap Down - Time to Sell?June 25, 2025 | marketbeat.comKymera: Sanofi Ends KT-474 Work, Will Advance KT-485June 25, 2025 | marketwatch.comGilead Sciences, Kymera Therapeutics Set Cancer-Drug CollaborationJune 25, 2025 | marketwatch.comGilead signs up to $750 million cancer drug deal with Kymera TherapeuticsJune 25, 2025 | reuters.comKymera Therapeutics Announces Sanofi IRAK4 Collaboration UpdateJune 25, 2025 | globenewswire.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $59.82 Consensus Price Target from BrokeragesJune 25, 2025 | americanbankingnews.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by GAMMA Investing LLCJune 23, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by BrokeragesJune 22, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Rhumbline AdvisersJune 18, 2025 | marketbeat.comHarbor Capital Advisors Inc. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)June 14, 2025 | marketbeat.comAnalysts Can't Get Enough of These Little-Known Biopharma StocksThree relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.June 12, 2025 | marketbeat.comStifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)June 8, 2025 | theglobeandmail.comStocks Showing Market Leadership: Kymera Therapeutics Earns 92 RS RatingJune 6, 2025 | msn.comB. Riley Reduces Earnings Estimates for Kymera TherapeuticsJune 6, 2025 | marketbeat.comAmeriprise Financial Inc. Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)June 6, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Trading 6.3% Higher - Here's What HappenedJune 5, 2025 | marketbeat.comLeerink Partnrs Has Bullish Forecast for KYMR Q2 EarningsJune 5, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $311,101.00 in StockJune 4, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $553,200.00 in StockJune 4, 2025 | marketbeat.comInsider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Sells 30,000 Shares of StockJune 4, 2025 | marketbeat.comBiotech and Social Media Stocks Defy Market Stagnation as Analysts Turn PositiveJune 4, 2025 | investing.comMorgan Stanley Upgrades Kymera Therapeutics (KYMR)June 4, 2025 | msn.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Jeffrey W. Albers Sells 6,349 SharesJune 4, 2025 | insidertrades.comKymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 DegraderJune 4, 2025 | insidermonkey.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.560.57▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼237▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News Today VTRS News Today ASND News Today MRNA News Today BBIO News Today BPMC News Today VRNA News Today ROIV News Today ELAN News Today RVMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
